CSL Behring
-
FDA Green Lights CSL Behring’s Privigen for New Use
King of Prussia’s CSL Behring has received more positive news for its autoimmune and inflammatory disease disorder drug Privigen, as…
-
King of Prussia’s CSL Behring to Acquire Calimmune for $91M
King of Prussia’s biotherapeutics company CSL Behring is acquiring Calimmune, a clinical-stage biotechnology company, for $91 million, writes Linda Loyd…
-
CSL Acquires Majority Interest in Chinese Plasma Business
Australia’s CSL Limited along with its CSL Behring business unit in King of Prussia has acquired a majority stake in…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
